Drug development for use during pregnancy: impact of the placenta

References

• Sneader W. Drug Discovery: a History. Wiley, NJ, USA (2005).
   Google Scholar
• Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet372(9643), 1073–1087 (2008).
   PubMed Web of Science ®Google Scholar
• Hai CM. Mechanistic systems biology of inflammatory gene expression in airway smooth muscle as tool for asthma drug development. Curr. Drug. Discov. Technol.5(4), 279–288 (2008).
   PubMedGoogle Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Econ.22(2), 151–185 (2003).
   PubMed Web of Science ®Google Scholar
• Shah S, Van Geijn H. Managing the risks of off-licence prescribing in pregnancy. Eur. J. Obstet. Gynecol.130, 156–159 (2007).
   Google Scholar
• Vernon JA, Golec JH, Dimasi JA. Drug development costs when financial risk is measured using the Fama–French three-factor model. Health Econ. DOI: 10.1002/hec.1538 (2009) (Epub ahead of print).
   Google Scholar
• Gedeon C, Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta27(8), 861–868 (2006).
   PubMed Web of Science ®Google Scholar
• Ward RM. Drug therapy of the fetus. J. Clin. Pharmacol.33(9), 780–789 (1993).
   PubMed Web of Science ®Google Scholar
• Brabin BJ, Romagosa C, Abdelgalil S et al. The sick placenta – the role of malaria. Placenta25(5), 359–378 (2004).
   PubMed Web of Science ®Google Scholar
• Hawcutt DB, Smyth RL. Drug development for children: how is pharma tackling an unmet need? IDrugs11(7), 502–507 (2008).
   PubMedGoogle Scholar
• Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin. Ther.30(11), 2133–2145 (2008).
   PubMed Web of Science ®Google Scholar
• Kapogiannis BG, Mattison DR. Adolescents in clinical trials. Clin. Pharmacol. Ther.84(6), 655–659 (2008).
   PubMed Web of Science ®Google Scholar
• Little BB. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet. Gynecol.93(5 Pt 2), 858–868 (1999).
   PubMed Web of Science ®Google Scholar
• Barbour V, Clark J, Peiperl L, Veitch E, Wong M, Yamey G. Drug development for maternal health cannot be left to the whims of the market. PLoS Med.5(6), e140 (2008).
   Google Scholar
• Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med.5(1), e22 (2008).
   PubMed Web of Science ®Google Scholar
• White NJ, McGready RM, Nosten FH. New medicines for tropical diseases in pregnancy: catch-22. PLoS Med.5(6), e133 (2008).
   PubMed Web of Science ®Google Scholar
• Chervenak FA, McCullough LB. Women and children first: transforming a historic defining moment into a contemporary ethical imperative. Am. J. Obstet. Gynecol.201(4), 351.e351–e355 (2009).
   PubMedGoogle Scholar
• DiMasi JA, Paquette C. The economics of follow-on drug research and development: trends in entry rates and the timing of development. Pharmacoeconomics22(2 Suppl. 2), 1–14 (2004).
   PubMed Web of Science ®Google Scholar
• Rayburn WF. A physician’s prerogative to prescribe drugs for off-label uses during pregnancy. Obstet. Gynecol.81(6), 1052–1055 (1993).
   PubMedGoogle Scholar
• Rayburn WF, Farmer KC. Off-label prescribing during pregnancy. Obstet. Gynecol. Clin. North Am.24(3), 471–478 (1997).
   PubMed Web of Science ®Google Scholar
• Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J. Law Med. Ethics37(3), 476–486, 396 (2009).
   PubMed Web of Science ®Google Scholar
• Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch. Intern. Med.169(19), 1745–1747 (2009).
   PubMed Web of Science ®Google Scholar
• Keiser MJ, Setola V, Irwin JJ et al. Predicting new molecular targets for known drugs. Nature462(7270), 175–181 (2009).
   PubMed Web of Science ®Google Scholar
• Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect.22(2), 119–125 (2009).
   PubMed Web of Science ®Google Scholar
• Mattison DR, Blann E, Malek A. Physiological alterations during pregnancy: impact on toxicokinetics. Fundam. Appl. Toxicol.16(2), 215–218 (1991).
   PubMedGoogle Scholar
• Granger JP. Maternal and fetal adaptations during pregnancy: lessons in regulatory and integrative physiology. Am. J. Physiol. Regul. Integr. Comp. Physiol.283(6), R1289–R1292 (2002).
   Google Scholar
• Chesnutt AN. Physiology of normal pregnancy. Crit. Care Clin.20(4), 609–615 (2004).
   PubMed Web of Science ®Google Scholar
• Norwitz ER, Edusa V, Park JS. Maternal physiology and complications of multiple pregnancy. Semin. Perinatol.29(5), 338–348 (2005).
   PubMed Web of Science ®Google Scholar
• Lee LK. Physiological adaptations of pregnancy affecting the nervous system. Semin. Neurol.27(5), 405–410 (2007).
   PubMedGoogle Scholar
• Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr. Drug Metab.10(5), 520–529 (2009).
   PubMed Web of Science ®Google Scholar
• Weier N, He SM, Li XT, Wang LL, Zhou SF. Placental drug disposition and its clinical implications. Curr. Drug Metab.9(2), 106–121 (2008).
   PubMedGoogle Scholar
• Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am. J. Gastroenterol.104(1), 228–233 (2009).
   PubMed Web of Science ®Google Scholar
• Myllynen P, Immonen E, Kummu M, Vähäkangas K. Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues. Expert Opin. Drug Metab. Toxicol.5(12), 1483–1499 (2009).
   PubMed Web of Science ®Google Scholar
• Sölder E, Rohr I, Kremser C, Hutzler P, Debbage PL. Imaging of placental transport mechanisms: a review. Eur. J. Obstet. Gynecol. Reprod. Biol.144(Suppl. 1), S114–S120 (2009).
   Google Scholar
• Andrade SE, Gurwitz JH, Davis RL et al. Prescription drug use in pregnancy. Am. J. Obstet. Gynecol.191(2), 398–407 (2004).
   PubMed Web of Science ®Google Scholar
• Lee E, Maneno MK, Smith L et al. National patterns of medication use during pregnancy. Pharmacoepidemiol. Drug Saf.15(8), 537–545 (2006).
   PubMed Web of Science ®Google Scholar
• Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br. J. Clin. Pharmacol.65(5), 653–660 (2008).
   PubMed Web of Science ®Google Scholar
• Colvin L, Slack-Smith L, Stanley FJ, Bower C. Pharmacovigilance in pregnancy using population-based linked datasets. Pharmacoepidemiol. Drug Saf.18(3), 211–225 (2009).
   PubMedGoogle Scholar
• Kebede B, Gedif T, Getachew A. Assessment of drug use among pregnant women in Addis Ababa, Ethiopia. Pharmacoepidemiol. Drug Saf.18(6), 462–468 (2009).
   PubMed Web of Science ®Google Scholar
• Viktil KK, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy – a population-based cohort study. Pharmacoepidemiol Drug Saf.18(8), 737–742 (2009).
   PubMed Web of Science ®Google Scholar
• Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: a population-based study in Regione Emilia–Romagna, Italy. Eur. J. Clin. Pharmacol.64, 1125–1132 (2008).
   PubMed Web of Science ®Google Scholar
• Schardein JL. Chemically Induced Birth Defects. Marcel Dekker, NY, USA (2000).
   Google Scholar
• Drugs During Pregnancy and Lactation. Treatment Options and Risk Assessment (2nd Edition). Schaefer C, Peters P, Miller RK (Eds). Elsevier, Amsterdam, The Netherlands (2007).
   Google Scholar
• Shepard TH, Lemire RJ. Catalog of Teratogenic Agents. Johns Hopkins University Press, MD, USA (2007).
   Google Scholar
• Sabath LD, Philipson A, Charles D. Ethics and the use of drugs during pregnancy. Science202(4367), 540–541 (1978).
   PubMedGoogle Scholar
• Chervenak FA, McCullough LB. A comprehensive ethical framework for fetal research and its application to fetal surgery for spina bifida. Am. J. Obstet. Gynecol.187(1), 10–14 (2002).
   PubMedGoogle Scholar
• Chervenak FA, McCullough LB, Birnbach DJ. Ethical issues in fetal surgery research. Best Pract. Res. Clin. Anaesthesiol.18(2), 221–230 (2004).
   PubMedGoogle Scholar
• Chervenak FA, McCullough LB. Ethics of maternal–fetal surgery. Semin. Fetal Neonatal Med.12(6), 426–431 (2007).
   PubMedGoogle Scholar
• Kilama WL. Ethical perspective on malaria research for Africa. Acta Trop.95(3), 276–284 (2005).
   PubMedGoogle Scholar
• Anger GJ, Piquette-Miller M. Pharmacokinetic studies in pregnant women. Clin. Pharmacol. Ther.83(1), 184–187 (2008).
   PubMed Web of Science ®Google Scholar
• Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol.15(6), 819–826 (2001).
   PubMed Web of Science ®Google Scholar
• Ellegard EK. Clinical and pathogenetic characteristics of pregnancy rhinitis. Clin. Rev. Allergy Immunol.26(3), 149–159 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet.44(10), 989–1008 (2005).
   PubMed Web of Science ®Google Scholar
• Muallem MM, Rubeiz NG. Physiological and biological skin changes in pregnancy. Clin. Dermatol.24, 80–83 (2006).
   PubMed Web of Science ®Google Scholar
• Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin. Drug Metab. Toxicol.3(4), 557–571 (2007).
   PubMed Web of Science ®Google Scholar
• Hill CC, Pickinpaugh J. Physiologic changes in pregnancy. Surg. Clin. N. Am.88, 391–401 (2008).
   PubMed Web of Science ®Google Scholar
• Chunilal SD, Bates SM. Venous thromboembolism in pregnancy: diagnosis, management and prevention. Thromb. Haemost.101(3), 428–438 (2009).
   PubMed Web of Science ®Google Scholar
• Ho SS, Yu WW, Lao TT, Chow DH, Chung JW, Li Y. Effectiveness of maternity support belts in reducing low back pain during pregnancy: a review. J. Clin. Nurs.18(11), 1523–1532 (2009).
   PubMed Web of Science ®Google Scholar
• Lindheimer MD, Taler SJ, Cunningham FG; American Society of Hypertension. ASH position paper: hypertension in pregnancy. J. Clin. Hypertens. (Greenwich)11(4), 214–225 (2009).
   PubMed Web of Science ®Google Scholar
• Wyska E, Jusko WJ. Approaches to pharmacokinetic/pharmacodynamic modeling during pregnancy. Semin. Perinatol.25(3), 124–132 (2001).
   PubMed Web of Science ®Google Scholar
• Tracy TS, Venkataramanan R, Glover DD, Caritis SN; National Institute for Child Health and Human Development Network of Maternal–Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am. J. Obstet. Gynecol.192(2), 633–639 (2005).
   PubMed Web of Science ®Google Scholar
• Frederiksen MC. A needed information source. Clin. Pharmacol. Ther.83(1), 22–23 (2008).
   PubMedGoogle Scholar
• Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet.48(3), 143–157 (2009).
   PubMed Web of Science ®Google Scholar
• Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics and pharmacogenetics: part II – workshop held at the National Institutes of Health, May 4–6, 1999. J. Womens Health11(8), 617–629 (2002).
   Google Scholar
• Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal–infant transfer of drugs during lactation. Expert Opin. Drug Metab. Toxicol.2(6), 947–960 (2006).
   PubMed Web of Science ®Google Scholar
• Mattison D, Zajicek A. Gaps in knowledge in treating pregnant women. Gend. Med.3(3), 169–182 (2006).
   PubMedGoogle Scholar
• Philipson A, Sabath LD, Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. Clin. Pharmacol. Ther.19(1), 68–77 (1976).
   PubMed Web of Science ®Google Scholar
• Philipson A. Pharmacokinetics of antibiotics in pregnancy and labour. Clin. Pharmacokinet.4(4), 297–309 (1979).
   PubMed Web of Science ®Google Scholar
• Yan R, Fokina V, Hankins GD, Ahmed MS, Nanovskaya TN. The effect of esterases on 17α-hydroxyprogesterone caproate. Am. J. Obstet. Gynecol.198(2), 229, e221–e225 (2008).
   PubMedGoogle Scholar
• Yan R, Nanovskaya TN, Zharikova OL, Mattison DR, Hankins GD, Ahmed MS. Metabolism of 17α-hydroxyprogesterone caproate by hepatic and placental microsomes of human and baboons. Biochem. Pharmacol.75(9), 1848–1857 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf.27(1), 25–61 (2004).
   PubMed Web of Science ®Google Scholar
• Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet.43(8), 487–514 (2004).
   PubMed Web of Science ®Google Scholar
• Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br. J. Clin. Pharmacol.66(2), 179–195 (2008).
   PubMed Web of Science ®Google Scholar
• Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br. J. Clin. Pharmacol.65(5), 667–673 (2008).
   PubMed Web of Science ®Google Scholar
• Hytten FE, Leitch I. The Physiology of Human Pregnancy. Blackwell Scientific Publications Ltd, Oxfordshire, UK (1971).
   Google Scholar
• Hytten FE. Physiological Adjustments in Pregnancy. WB Saunders, PA, USA (1975).
   Google Scholar
• Borg-Stein J, Dugan SA, Gruber J. Musculoskeletal aspects of pregnancy. Am. J. Phys. Med. Rehabil.84, 180–192 (2005).
   PubMed Web of Science ®Google Scholar
• Fox MW, Harms RW, Davis DH. Selected neurologic complications of pregnancy. Mayo Clin. Proc.65(12), 1595–1618 (1990).
   PubMed Web of Science ®Google Scholar
• Carlin A, Alfirevic Z. Physiological changes of pregnancy and monitoring. Best Pract. Res. Clin. Obstet. Gynaecol.22(5), 801–823 (2008).
   PubMed Web of Science ®Google Scholar
• Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin. Perinatol.25(3), 120–123 (2001).
   PubMed Web of Science ®Google Scholar
• Abbas AE, Lester SJ, Connolly H. Pregnancy and the cardiovascular system. Int. J. Cardiol.98, 179–189 (2005).
   PubMed Web of Science ®Google Scholar
• Lohsiriwat S, Imrittha N. Effect of posture on creatinine clearance in late pregnancy and after pregnancy. J. Obstet. Gynaecol. Res.34(3), 337–342 (2008).
   PubMedGoogle Scholar
• Ganzevoort W, Rep A, Bonsel GJ, de Vries JI, Wolf H. Plasma volume and blood pressure regulation in hypertensive pregnancy. J. Hypertens.22, 1235–1242 (2004).
   PubMed Web of Science ®Google Scholar
• Qasqas SA, McPherson C, Frishman WH, Elkayam U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Cardiol. Rev.12(4), 201–221 (2004).
   PubMedGoogle Scholar
• Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am. J. Cardiol.97(8), 1206–1212 (2006).
   PubMed Web of Science ®Google Scholar
• Magee LA, von Dadelszen P. The management of severe hypertension. Semin. Perinatol.33(3), 138–142 (2009).
   PubMedGoogle Scholar
• Hartman-Craven B, Christofides A, O’Connor DL, Zlotkin S. Relative bioavailability of iron and folic acid from a new powdered supplement compared to a traditional tablet in pregnant women. BMC Pregnancy Childbirth9, 33 (2009).
   PubMed Web of Science ®Google Scholar
• James AH. Venous thromboembolism in pregnancy. Arterioscler. Thromb. Vasc. Biol.29(3), 326–331 (2009).
   PubMed Web of Science ®Google Scholar
• Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb. Haemost.52(2), 176–182 (1984).
   PubMed Web of Science ®Google Scholar
• Gibson PS, Powrie R. Anticoagulants and pregnancy: when are they safe? Cleve. Clin. J. Med.76(2), 113–127 (2009).
   PubMed Web of Science ®Google Scholar
• Clark NP, Delate T, Witt DM, Parker S, McDuffie R. A descriptive evaluation of unfractionated heparin use during pregnancy. J. Thromb. Thrombolysis27(3), 267–273 (2009).
   PubMed Web of Science ®Google Scholar
• Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am. J. Obstet. Gynecol.173(4), 1240–1245 (1995).
   PubMed Web of Science ®Google Scholar
• Crowther MA, Spitzer K, Julian J et al. Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study. Thromb. Res.98(2), 133–138 (2000).
   PubMed Web of Science ®Google Scholar
• Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am. J. Obstet. Gynecol.191(3), 1024–1029 (2004).
   PubMed Web of Science ®Google Scholar
• Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb. Haemost.92(4), 791–796 (2004).
   PubMed Web of Science ®Google Scholar
• Schatz M, Dombrowski MP, Wise R et al. Spirometry is related to perinatal outcomes in pregnant women with asthma. Am. J. Obstet. Gynecol.194(1), 120–126 (2006).
   PubMed Web of Science ®Google Scholar
• Jensen D, Duffin J, Lam YM et al. Physiological mechanisms of hyperventilation during human pregnancy. Respir. Physiol. Neurobiol.161(1), 76–86 (2008).
   PubMedGoogle Scholar
• Crapo RO. Normal cardiopulmonary physiology during pregnancy. Clin. Obstet. Gynecol.39(1), 3–16 (1996).
   PubMed Web of Science ®Google Scholar
• Dombrowski MP. Asthma and pregnancy. Obstet. Gynecol.108(3 Pt 1), 667–681 (2006).
   PubMed Web of Science ®Google Scholar
• Schatz M. Is maternal asthma a life or death issue for the baby? Thorax64(2), 93–95 (2009).
   PubMed Web of Science ®Google Scholar
• Schatz M, Dombrowski MP. Clinical practice. Asthma in pregnancy. N. Engl. J. Med.360(18), 1862–1869 (2009).
   PubMed Web of Science ®Google Scholar
• Tan KS, Thomson NC. Asthma in pregnancy. Am. J. Med.109(9), 727–733 (2000).
   PubMed Web of Science ®Google Scholar
• Beck SA. Asthma in the female: hormonal effect and pregnancy. Allergy Asthma Proc.22, 1–4 (2001).
   PubMedGoogle Scholar
• Schatz M. The efficacy and safety of asthma medications during pregnancy. Semin. Perinatol.25(3), 145–152 (2001).
   PubMed Web of Science ®Google Scholar
• Murphy VE, Gibson PG, Talbot PI, Kessell CG, Clifton VL. Asthma self-management skills and the use of asthma education during pregnancy. Eur. Respir. J.26(3), 435–441 (2005).
   PubMed Web of Science ®Google Scholar
• NHLBI. Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment Update 2004. National Heart Lung and Blood Institute, NIH Publication 05–5236 (2005).
   Google Scholar
• Siddiqui S, Goodman N, McKenna S, Goldie M, Waugh J, Brightling CE. Pre-eclampsia is associated with airway hyperresponsiveness. BJOG115(4), 520–522 (2008).
   PubMed Web of Science ®Google Scholar
• Bakhireva LN, Schatz M, Jones KL, Chambers CD. Asthma control during pregnancy and the risk of preterm delivery or impaired fetal growth. Ann. Allergy Asthma Immunol.101(2), 137–143 (2008).
   PubMed Web of Science ®Google Scholar
• Blais L, Forget A. Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women. J. Allergy Clin. Immunol.121(6), 1379–1384, 1384.e1371 (2008).
   PubMed Web of Science ®Google Scholar
• Lin S, Munsie JP, Herdt-Losavio ML et al. Maternal asthma medication use and the risk of gastroschisis. Am. J. Epidemiol.168(1), 73–79 (2008).
   PubMed Web of Science ®Google Scholar
• Lin S, Herdt-Losavio M, Gensburg L, Marshall E, Druschel C. Maternal asthma, asthma medication use, and the risk of congenital heart defects. Birth Defects Res. Part A Clin. Mol. Teratol.85(2), 161–168 (2009).
   PubMed Web of Science ®Google Scholar
• Clifton VL, Rennie N, Murphy VE. Effect of inhaled glucocorticoid treatment on placental 11β-hydroxysteroid dehydrogenase type 2 activity and neonatal birthweight in pregnancies complicated by asthma. Aust. N. Z. J. Obstet. Gynaecol.46(2), 136–140 (2006).
   PubMed Web of Science ®Google Scholar
• Mayhew TM, Jenkins H, Todd B, Clifton VL. Maternal asthma and placental morphometry: effects of severity, treatment and fetal sex. Placenta29(4), 366–373 (2008).
   PubMed Web of Science ®Google Scholar
• Ballabh P, Lo ES, Kumari J et al. Pharmacokinetics of betamethasone in twin and singleton pregnancy. Clin. Pharmacol. Ther.71(1), 39–45 (2002).
   PubMed Web of Science ®Google Scholar
• Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy. Safety considerations. Drug Saf.20(4), 361–375 (1999).
   PubMedGoogle Scholar
• Demoly P, Piette V, Daures JP. Treatment of allergic rhinitis during pregnancy. Drugs63(17), 1813–1820 (2003).
   PubMed Web of Science ®Google Scholar
• Osur SL. The management of asthma and rhinitis during pregnancy. J. Womens Health (Larchmt)14(3), 263–276 (2005).
   PubMedGoogle Scholar
• Yawn B, Knudtson M. Treating asthma and comorbid allergic rhinitis in pregnancy. J. Am. Board Fam. Med.20(3), 289–298 (2007).
   PubMed Web of Science ®Google Scholar
• Venkata C, Venkateshiah SB. Sleep-disordered breathing during pregnancy. J. Am. Board Fam. Med.22(2), 158–168 (2009).
   PubMed Web of Science ®Google Scholar
• Hornby PJ, Abrahams TP. Pulmonary pharmacology. Clin. Obstet. Gynecol.39(1), 17–35 (1996).
   PubMedGoogle Scholar
• Fabre E, Tajada M, González de Agüero R et al. Use of drugs in pulmonary medicine in pregnant women. Clin. Pulm. Med.9(1), 20–32 (2002).
   Google Scholar
• Piette V, Daures JP, Demoly P. Treating allergic rhinitis in pregnancy. Curr. Allergy Asthma Rep.6(3), 232–238 (2006).
   PubMedGoogle Scholar
• Garavello W, Somigliana E, Acaia B, Gaini L, Pignataro L, Gaini RM. Nasal lavage in pregnant women with seasonal allergic rhinitis: a randomized study. Int. Arch. Allergy Immunol.151(2), 137–141 (2009).
   PubMedGoogle Scholar
• Chatfield WR, Schramm BM, Richmond WJ. The absorption of ampicillin in late pregnancy and labour. N. Z. Med. J.80(529), 500–501 (1974).
   PubMedGoogle Scholar
• Juon AM, Kühn-Velten WN, Burkhardt T, Krähenmann F, Zimmermann R, von Mandach U. Nifedipine gastrointestinal therapeutic system (GITS) as an alternative to slow-release for tocolysis – tolerance and pharmacokinetic profile. Eur. J. Obstet. Gynecol. Reprod. Biol.140(1), 27–32 (2008).
   PubMedGoogle Scholar
• Silberschmidt AL, Kühn-Velten WN, Juon AM, Zimmermann R, von Mandach U. Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. BJOG115(4), 480–485 (2008).
   PubMedGoogle Scholar
• Bynum TE. Hepatic and gastrointestinal disorders in pregnancy. Med. Clin. North. Am.61(1), 129–138 (1977).
   PubMed Web of Science ®Google Scholar
• Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N. Engl. J. Med.360(24), 2528–2535 (2009).
   PubMed Web of Science ®Google Scholar
• Richter JE. Review article: the management of heartburn in pregnancy. Aliment. Pharmacol. Ther.22(9), 749–757 (2005).
   PubMed Web of Science ®Google Scholar
• Vlastarakos PV, Manolopoulos L, Ferekidis E, Antsaklis A, Nikolopoulos TP. Treating common problems of the nose and throat in pregnancy: what is safe? Eur. Arch. Otorhinolaryngol.265(5), 499–508 (2008).
   PubMed Web of Science ®Google Scholar
• Gill SK, O’Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am. J. Gastroenterol.104(6), 1541–1545 (2009).
   PubMedGoogle Scholar
• Philipson A. Pharmacokinetics of ampicillin during pregnancy. J. Infect. Dis.136(3), 370–376 (1977).
   PubMed Web of Science ®Google Scholar
• Frederiksen MC, Ruo TI, Chow MJ, Atkinson AJ Jr. Theophylline pharmacokinetics in pregnancy. Clin. Pharmacol. Ther.40(3), 321–328 (1986).
   PubMed Web of Science ®Google Scholar
• Philipson A. The use of antibiotics in pregnancy. J. Antimicrob. Chemother.12(2), 101–102 (1983).
   PubMedGoogle Scholar
• Philipson A. Plasma levels of ampicillin in pregnant women following administration of ampicillin and pivampicillin. Am. J. Obstet. Gynecol.130(6), 674–683 (1978).
   PubMedGoogle Scholar
• Chamberlain A, White S, Bawdon R, Thomas S, Larsen B. Pharmacokinetics of ampicillin and sulbactam in pregnancy. Am. J. Obstet. Gynecol.168(2), 667–673 (1993).
   PubMed Web of Science ®Google Scholar
• Bint A, Bullock D, Reeves D, Wilkinson P. A comparative trial of pivmecillinam and ampicillin in bacteriuria of pregnancy. Infection7(6), 290–293 (1979).
   PubMedGoogle Scholar
• Philipson A. Persistance of ampicillin in the intrauterine content following single and multiple doses to pregnant women. Acta Obstet. Gynecol. Scand.60(2), 121–123 (1981).
   PubMedGoogle Scholar
• Pacifici GM. Placental transfer of antibiotics administered to the mother: a review. Int. J. Clin. Pharmacol. Ther.44(2), 57–63 (2006).
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Prasad PD. Role of transporters in placental transfer of drugs. Toxicol. Appl. Pharmacol.207(Suppl. 2), 381–387 (2005).
   PubMedGoogle Scholar
• Atkinson DE, Brice-Bennett S, D’Souza SW. Antiepileptic medication during pregnancy: does fetal genotype affect outcome? Pediatr. Res.62(2), 120–127 (2007).
   PubMed Web of Science ®Google Scholar
• Boeuf P, Tan A, Romagosa C et al. Placental hypoxia during placental malaria. J. Infect. Dis.197(5), 757–765 (2008).
   PubMedGoogle Scholar
• Ito S. Transplacental treatment of fetal tachycardia: implications of drug transporting proteins in placenta. Semin. Perinatol.25(3), 196–201 (2001).
   PubMed Web of Science ®Google Scholar
• Kopecky EA, Simone C, Knie B, Koren G. Transfer of morphine across the human placenta and its interaction with naloxone. Life Sci.65(22), 2359–2371 (1999).
   PubMedGoogle Scholar
• Pastrakuljic A, Schwartz R, Simone C, Derewlany LO, Knie B, Koren G. Transplacental transfer and biotransformation studies of nicotine in the human placental cotyledon perfused in vitro. Life Sci.63(26), 2333–2342 (1998).
   PubMed Web of Science ®Google Scholar
• Sastry BV, Chance MB, Hemontolor ME, Goddijn-Wessel TA. Formation and retention of cotinine during placental transfer of nicotine in human placental cotyledon. Pharmacology57(2), 104–116 (1998).
   PubMed Web of Science ®Google Scholar
• Simone C, Byrne BM, Derewlany LO, Oskamp M, Koren G. The transfer, of cocaethylene across the human term placental cotyledon perfused in vitro. Reprod. Toxicol.11(2–3), 215–219 (1997).
   PubMedGoogle Scholar
• Nekhayeva IA, Nanovskaya TN, Deshmukh SV, Zharikova OL, Hankins GD, Ahmed MS. Bidirectional transfer of methadone across human placenta. Biochem. Pharmacol.69(1), 187–197 (2005).
   PubMed Web of Science ®Google Scholar
• Nanovskaya TN, Nekhayeva IA, Hankins GD, Ahmed MS. Transfer of methadone across the dually perfused preterm human placental lobule. Am. J. Obstet. Gynecol.198(1), 126.e1–4 (2008).
   PubMedGoogle Scholar
• Malek A, Obrist C, Wenzinger S, von Mandach U. The impact of cocaine and heroin on the placental transfer of methadone. Reprod. Biol. Endocrinol.7, 61–69 (2009).
   PubMed Web of Science ®Google Scholar
• Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L. Maternal–fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am. J. Obstet. Gynecol.185(1), 178–181 (2001).
   PubMed Web of Science ®Google Scholar
• Olivero OA, Parikka R, Poirier MC, Vahakangas K. 30-azido-30-deoxythymidine (AZT) transplacental perfusion kinetics and DNA incorporation in normal human placentas perfused with AZT. Mutat. Res.428(1–2), 41–47 (1999).
   PubMed Web of Science ®Google Scholar
• Boal JH, Plessinger MA, van den Reydt C, Miller RK. Pharmacokinetic and toxicity studies of AZT (zidovudine) following perfusion of human term placenta for 14 hours. Toxicol. Appl. Pharmacol.143(1), 13–21 (1997).
   PubMedGoogle Scholar
• Gavard L, Gil S, Peytavin G et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am. J. Obstet. Gynecol.195(1), 296–301 (2006).
   PubMed Web of Science ®Google Scholar
• Ceccaldi PF, Ferreira C, Gavard L, Gil S, Peytavin G, Mandelbrot L. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am. J. Obstet. Gynecol.198(4), 433.e1–2 (2008).
   PubMedGoogle Scholar
• Gavard L, Beghin D, Forestier FP et al. Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir. Eur. J. Obstet. Gynecol. Reprod. Biol.147(2), 157–160 (2009).
   PubMedGoogle Scholar
• Heikkinen T, Ekblad U, Laine K. Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. Psychopharmacology (Berl.)153(4), 450–454 (2001).
   PubMed Web of Science ®Google Scholar
• Casey B, Bawdon RE. Ex vivo human placental transfer of trovafloxacin. Infect. Dis. Obstet. Gynecol.8(5–6), 228–229 (2000).
   PubMedGoogle Scholar
• Polachek H, Holcberg G, Sapir GP et al. Transfer of ciprofloxacin, ofloxacin and levofloxacin across the perfused human placenta in vitro. Eur. J. Obstet. Gynecol. Reprod. Biol.122(1), 61–65 (2005).
   PubMed Web of Science ®Google Scholar
• Hnat MD, Gainer J, Bawdon RE, Wendel GD Jr. Transplacental passage of vancomycin in the ex vivo human perfusion model. Infect. Dis. Obstet. Gynecol.12(2), 57–61 (2004).
   PubMedGoogle Scholar
• Worley KC, Roberts SW, Bawdon RE. The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Infect. Dis. Obstet. Gynecol.927574 (2008).
   PubMedGoogle Scholar
• Holmes HJ, Casey BM, Bawdon RE. Placental transfer of rosiglitazone in the ex vivo human perfusion model. Am. J. Obstet. Gynecol.195(6), 1715–1719 (2006).
   PubMed Web of Science ®Google Scholar
• Ray JG, Boskovic R, Knie B, Hard M, Portnoi G, Koren G. In vitro analysis of human transplacental transport of desmopressin. Clin. Biochem.37(1), 10–13 (2004).
   PubMedGoogle Scholar
• Nanovskaya TN, Nekhayeva I, Hankins GD, Ahmed MS. Effect of human serum albumin on transplacental transfer of glyburide. Biochem. Pharmacol.72(5), 632–639 (2006).
   PubMed Web of Science ®Google Scholar
• Pollex E, Lubetsky A, Koren G. The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta29(8), 743–747 (2008).
   PubMed Web of Science ®Google Scholar
• Kovo M, Haroutiunian S, Feldman N, Hoffman A, Glezerman M. Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. Eur. J. Obstet. Gynecol. Reprod. Biol.136(1), 29–33 (2008).
   PubMed Web of Science ®Google Scholar
• Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care26(5), 1390–1394 (2003).
   PubMed Web of Science ®Google Scholar
• Holcberg G, Tsadkin-Tamir M, Sapir OP et al. Transfer of insulin lispro across the human placenta. Eur. J. Obstet. Gynecol. Reprod. Biol.115(1), 117–118 (2004).
   PubMed Web of Science ®Google Scholar
• la-Kokko TI, Pienimaki P, Herva R, Hollmen AI, Pelkonen O, Vahakangas K. Transfer of lidocaine and bupivacaine across the isolated perfused human placenta. Pharmacol. Toxicol.77(2), 142–148 (1995).
   PubMedGoogle Scholar
• Herman NL, Li AT, Van Decar TK et al. Transfer of methohexital across the perfused human placenta. J. Clin. Anesth.12(1), 25–30 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson RF, Cahana A, Olenick MP et al. A comparison of the placental transfer of ropivacaine versus bupivacaine. Anesth. Analg.89(3), 703–708 (1999).
   PubMed Web of Science ®Google Scholar
• Giroux M, Teixera MG, Dumas JC, Desprats R, Grandjean H, Houin G. Influence of maternal blood flow on the placental transfer of three opioids – fentanyl, alfentanil, sufentanil. Biol. Neonate72(3), 133–141 (1997).
   PubMedGoogle Scholar
• Pienimaki P, Lampela E, Hakkola J, Arvela P, Raunio H, Vahakangas K. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia38(3), 309–316 (1997).
   PubMed Web of Science ®Google Scholar
• Myllynen PK, Pienimaki PK, Vahakangas KH. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur. J. Clin. Pharmacol.58(10), 677–682 (2003).
   PubMed Web of Science ®Google Scholar
• Magee KP, Bawdon RE. Ex vivo human placental transfer and the vasoactive properties of hydralazine. Am. J. Obstet. Gynecol.182(1), 167–169 (2000).
   PubMed Web of Science ®Google Scholar
• Mortimer RH, Cannell GR, Addison RS, Johnson LP, Roberts MS, Bernus I. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J. Clin. Endocrinol. Metab.82(9), 3099–3102 (1997).
   PubMed Web of Science ®Google Scholar
• Schmolling J, Jung S, Reinsberg J, Schlebusch H. Diffusion characteristics of placental preparations affect the digoxin passage across the isolated placental lobule. Ther. Drug Monit.19(1), 11–16 (1997).
   PubMedGoogle Scholar
• Mose T, Knudsen LE, Hedegaard M, Mortensen GK. Transplacental transfer of monomethyl phthalate and mono(2-ethylhexyl) phthalate in a human placenta perfusion system. Int. J. Toxicol.26(3), 221–229 (2007).
   PubMed Web of Science ®Google Scholar
• Myren M, Mose T, Mathiesen L, Knudsen LE. The human placenta – an alternative for studying foetal exposure. Toxicol. In Vitro.21, 1332–1340 (2007).
   PubMed Web of Science ®Google Scholar
• Fox H. A contemporary view of the human placenta. Midwifery7, 31–39 (1991).
   PubMedGoogle Scholar
• van der Aa EM, Peereboom-Stegeman JH, Noordhoek J, Gribnau FW, Russel FG. Mechanisms of drug transfer across the human placenta. Pharm. World Sci.20, 139–148 (1998).
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Frank HG. Placental development. In: Fetal and Neonatal Physiology. Polin RA, Fox WW, Abman SH (Eds). Saunders, London, UK, 85–97 (2004).
   Google Scholar
• Simone C, Derewlany LO, Koren G. Drug transfer across the placenta. Considerations in treatment and research. Clin. Perinatol.21, 463–481 (1994).
   PubMed Web of Science ®Google Scholar
• Ganapathy V, Prasad PD, Ganapathy ME, Leibach FH. Placental transporters relevant to drug distribution across the maternal–fetal interface. J. Pharmacol. Exp. Ther.294, 413–420 (2000).
   PubMed Web of Science ®Google Scholar
• Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am. J Gastroenterol.104, 228–233 (2009).
   PubMed Web of Science ®Google Scholar
• Bawdon RE, Kaul S, Sobhi S. The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol. Obstet. Invest.38(1), 1–4 (1994).
   PubMed Web of Science ®Google Scholar
• Gilstrap LC, Bawdon RE, Roberts SW, Sobhi S. The transfer of the nucleoside analog ganciclovir across the perfused human placenta. Am. J. Obstet. Gynecol.170(4), 967–972 (1994).
   PubMed Web of Science ®Google Scholar
• Pienimäki P, Hartikainen AL, Arvela P et al. Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia36(3), 241–248 (1995).
   PubMedGoogle Scholar
• Malek A, Blann E, Mattison DR. Human placental transport of oxytocin. J. Matern. Fetal Med.5(5), 245–255 (1996).
   PubMedGoogle Scholar
• Bawdon RE. Ex vivo human placental transfer of anti-human immunodeficiency virus compounds. Infect. Dis. Obstet. Gynecol.5(4), 310–315 (1997).
   PubMedGoogle Scholar
• Bloom SL, Dias KM, Bawdon RE, Gilstrap LC 3rd. The maternal–fetal transfer of lamivudine in the ex vivo human placenta. Am. J. Obstet. Gynecol.176(2), 291–293 (1997).
   PubMed Web of Science ®Google Scholar
• Peytavin G, Leng JJ, Forestier F, Saux M, Hohlfeld P, Farinotti R. Placental transfer of pyrimethamine studied in an ex vivo placental perfusion model. Biol. Neonate78(2), 83–85 (2000).
   PubMedGoogle Scholar
• Gavard L, Gil S, Peytavin G et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am. J. Obstet. Gynecol.195(1), 296–301 (2006).
   PubMed Web of Science ®Google Scholar
• Hewitt M, Madden JC, Rowe PH, Cronin MT. Structure-based modelling in reproductive toxicology: (Q)SARs for the placental barrier. SAR QSAR Environ. Res.18(1–2), 57–76 (2007).
   PubMed Web of Science ®Google Scholar
• He YL, Seno H, Sasaki K, Tashiro C. The influences of maternal albumin concentrations on the placental transfer of propofol in human dually perfused cotyledon in vitro. Anesth. Analg.94(5), 1312–1314 (2002).
   PubMedGoogle Scholar
• Nanovskaya TN, Patrikeeva S, Hemauer S et al. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. J. Matern. Fetal Neonatal Med.21(3), 197–207 (2008).
   PubMed Web of Science ®Google Scholar
• Gulati A, Boudinot FD, Gerk PM. Binding of lopinavir to human α1-acid glycoprotein and serum albumin. Drug Metab. Dispos.37(8), 1572–1575 (2009).
   PubMedGoogle Scholar
• Schrier RW, Cadnapaphornchai MA, Ohara M. Water retention and aquaporins in heart failure, liver disease and pregnancy. J. R. Soc. Med.94(6), 265–269 (2001).
   PubMed Web of Science ®Google Scholar
• Riquelme G. Placental chloride channels: a review. Placenta30(8), 659–669 (2009).
   PubMed Web of Science ®Google Scholar
• Illsley NP. Glucose transporters in the human placenta. Placenta21(1), 14–22 (2000).
   PubMed Web of Science ®Google Scholar
• Kovo M, Kogman N, Ovadia O, Nakash I, Golan A, Hoffman A. Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenat. Diagn.28(6), 544–548 (2008).
   PubMed Web of Science ®Google Scholar
• Cleal JK, Lewis RM. The mechanisms and regulation of placental amino acid transport to the human foetus. J. Neuroendocrinol.20(4), 419–426 (2008).
   PubMedGoogle Scholar
• Grillo MA, Lanza A, Colombatto S. Transport of amino acids through the placenta and their role. Amino Acids34(4), 517–523 (2008).
   PubMedGoogle Scholar
• Unadkat JD, Dahlin A, Vijay S. Placental drug transporters. Curr. Drug Metab.5(1), 125–131 (2004).
   PubMed Web of Science ®Google Scholar
• Cetin I, Alvino G. Intrauterine growth restriction: implications for placental metabolism and transport. A review. Placenta30(Suppl. A), S77–S82 (2009).
   PubMed Web of Science ®Google Scholar
• Jansson T, Myatt L, Powell TL. The role of trophoblast nutrient and ion transporters in the development of pregnancy complications and adult disease. Curr. Vasc. Pharmacol.7(4), 521–533 (2009).
   PubMed Web of Science ®Google Scholar
• Brambell FW, Halliday R, Brierley J, Hemmings WA. Transference of passive immunity from mother to young. Lancet266, 964–965 (1954).
   PubMedGoogle Scholar
• Leach JL, Sedmak DD, Osborne JM et al. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal–fetal antibody transport. J. Immunol.157, 3317–3322 (1996).
   PubMed Web of Science ®Google Scholar
• Kim J, Mohanty S, Ganesan LP et al. FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus. J. Immunol.182, 2583–2589 (2009).
   PubMedGoogle Scholar
• MacDonald NE, Riley LE, Steinhoff MC. Influenza immunization in pregnancy. Obstet. Gynecol.114(2 Pt 1), 365–368 (2009).
   PubMedGoogle Scholar
• Potter RC, Gonik B. Prevention of influenza in mothers and infants. Expert Rev. Vaccines8(2), 149–152 (2009).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, De Serres G. Is routine influenza immunization warranted in early pregnancy? Vaccine27(35), 4754–4770 (2009).
   PubMed Web of Science ®Google Scholar
• Vahakangas K, Myllynen P. Drug transporters in the human blood–placental barrier. Br. J. Pharmacol.158(3), 665–678 (2009).
   PubMed Web of Science ®Google Scholar
• Carter AM. Placental oxygen consumption, part I: in vivo studies. Placenta21(Suppl. A), 31–37 (2000).
   Google Scholar
• Schneider H. Placental oxygen consumption, part II: in vitro studies – a review. Placenta21(Suppl. A), S38–S44 (2000).
   PubMedGoogle Scholar
• Schneider H. Tolerance of human placental tissue to severe hypoxia and its relevance for dual ex vivo perfusion. Placenta30(Suppl. A), S71–S76 (2009).
   Google Scholar
• Murer H, Kinne R. The use of isolated membrane vesicles to study epithelial transport processes. J. Membr. Biol.55, 81–95 (1980).
   PubMed Web of Science ®Google Scholar
• Bissonnette JM. Membrane vesicles from trophoblast cells as models for placental exchange studies. Placenta3, 99–106 (1982).
   PubMedGoogle Scholar
• Baumann MU, Deborde S, Illsley NP. Placental glucose transfer and fetal growth. Endocrine19(1), 13–22 (2002).
   PubMed Web of Science ®Google Scholar
• Ushigome F, Koyabu N, Satoh S et al. Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles. Pharm. Res.20(1), 38–44 (2003).
   PubMed Web of Science ®Google Scholar
• Hemmings DG, Lowen B, Sherburne R, Sawicki G, Guilbert LJ. Villous trophoblasts cultured on semi-permeable membranes form an effective barrier to the passage of high and low molecular weight particles. Placenta22, 70–79 (2001).
   PubMed Web of Science ®Google Scholar
• Sullivan MHF. Endocrine cell lines from the placenta. Mol. Cell. Endocrinol.228, 109–119 (2002).
   Google Scholar
• Miller RK, Genbacev O, Turner MA, Aplin JD, Caniggia I, Huppertz B. Human placental explants in culture: approaches and assessments. Placenta26, 439–448 (2005).
   PubMed Web of Science ®Google Scholar
• Polliotti BM, Abramowsky C, Schwartz DA et al. Culture of first-trimester and full-term human chorionic villus explants: role of human chorionic gonadotropin and human placental lactogen as a viability index. Early Pregnancy1, 270–280 (1995).
   PubMedGoogle Scholar
• Palmer ME, Watson AL, Burton GJ. Morphological analysis of degeneration and regeneration of syncytitrophoblast in first trimester placental villi during organ culture. Hum. Reprod.12, 379–382 (1997).
   PubMed Web of Science ®Google Scholar
• Siman CM, Sibley CP, Jones CJP, Turner MA, Greenwood SL. The functional regeneration of syncytiotrophoblast in cultured explants of term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol.280, R1116 (2001).
   PubMed Web of Science ®Google Scholar
• Sooranna SR, Oteng-Ntim E, Meah R, Ryder TA, Bajoria R. Characterization of human placental explants morphological, biochemical and physiological studies using first and third trimester placenta. Hum. Reprod.14, 536–541 (1999).
   PubMed Web of Science ®Google Scholar
• Cedard L, Yannotti S, Varangot J. The perfusion of the placenta in vitro used in the study of the biosynthesis of estrogens. C. R. Seances Soc. Biol. Fil.155, 458–461 (1961).
   PubMedGoogle Scholar
• Klinge E, Mattila MJ, Penttila O, Jukarainen E. Influence of drugs on vasoactive peptides and amines in perfused human placenta. Ann. Med. Exp. Biol. Fenn.44, 369–375 (1966).
   PubMedGoogle Scholar
• Hensleigh PA, Krantz KE. Extracorporeal perfusion of the human placenta. I. Placental transfer of ascorbic acid. Am. J. Obstet. Gynecol.96, 5–13 (1966).
   PubMedGoogle Scholar
• Panigel M, Pascaud M, Brun JL. Radioangiographic study of circulation in the villi and intervillous space of isolated human placental cotyledon kept viable by perfusion. J. Physiol. (Paris)59, 277 (1967).
   PubMedGoogle Scholar
• Nesbitt RE Jr, Rice PA, Rourke JE, Torresi VF, Souchay AM. In vitro perfusion studies of the human placenta. A newly-designed apparatus for extracorporeal perfusion achieving dual closed circulation. Gynecol. Invest.1, 185–203 (1970).
   PubMedGoogle Scholar
• Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am. J. Obstet. Gynecol.114, 822–828 (1972).
   PubMed Web of Science ®Google Scholar
• Miller RK, Wier PJ, Maulik D, di Sant’Agnese PA. Human placenta in vitro: characterization during 12 h of dual perfusion. Contrib. Gynecol. Obstet.13, 77–84 (1985).
   PubMedGoogle Scholar
• Malek A, Leiser R. Influence of the magnesium aspartate hydrochloride administration to the maternal circuit on the aspartate concentration of the fetal circuit under in vitro perfusion of human placenta. Eur. J. Obstet. Gynecol. Reprod. Biol.142(1), 12–17 (2009).
   PubMedGoogle Scholar
• Rahi MM, Heikkinen TM, Hakala KE, Laine KP. The effect of probenecid and MK-571 on the feto–maternal transfer of saquinavir in dually perfused human term placenta. Eur. J. Pharm. Sci.37(5), 588–592 (2009).
   PubMedGoogle Scholar
• Shintaku K, Hori S, Tsujimoto M et al. Transplacental pharmacokinetics of diclofenac in perfused human placenta. Drug Metab. Dispos.37(5), 962–968 (2009).
   PubMedGoogle Scholar
• Earhart AD, Patrikeeva S, Wang X et al. Transplacental transfer and metabolism of bupropion. J. Matern. Fetal Neonatal Med.1–10 (2009).
   Google Scholar
• Bajoria R, Fisk NM. Permeability of human placenta and fetal membranes to thyrotropin-stimulating hormone in vitro. Pediatr. Res.43, 621–628 (1998).
   PubMedGoogle Scholar
• Schneider H, Dancis J. In vitro human placental perfusion of human placenta. Trophoblast Res.2, 597–605 (1987).
   Google Scholar
• Schmolling J, Brunken M, Richter O, Ulrich U, Schmidt S, Krebs D. Photoradiation of perfused placental tissue – a suitable in vitro model for photodynamic therapy? Arch. Gynecol. Obstet.265, 199–203 (2001).
   PubMedGoogle Scholar
• Juric S, Newport DJ, Ritchie JC, Galanti M, Stowe ZN. Zolpidem (Ambien®) in pregnancy: placental passage and outcome. Arch. Womens Ment. Health12(6), 441–446 (2009).
   PubMed Web of Science ®Google Scholar
• Muller AE, Oostvogel PM, DeJongh J et al. Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera. Antimicrob. Agents Chemother.53(4), 1574–1580 (2009).
   PubMedGoogle Scholar
• Whyatt RM, Garfinkel R, Hoepner LA et al. A biomarker validation study of prenatal chlorpyrifos exposure within an inner-city cohort during pregnancy. Environ. Health Perspect.117(4), 559–567 (2009).
   PubMed Web of Science ®Google Scholar
• Sastry BV. Techniques to study human placental transport. Adv. Drug. Deliv. Rev.38, 17–39 (1999).
   PubMed Web of Science ®Google Scholar
• Aitken RJ, Chaudhry MQ, Boxall AB, Hull M. Manufacture and use of nanomaterials: current status in the UK and global trends. Occup. Med. (Lond.)56, 300–306 (2006).
   Google Scholar
• Maynard AD. Nanotechnology: the next big thing, or much ado about nothing? Ann. Occup. Hyg.51, 1–12 (2007).
   PubMed Web of Science ®Google Scholar
• Oberdörster G, Maynard A, Donaldson K et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre Toxicol.2, 8 (2005).
   PubMed Web of Science ®Google Scholar
• Seaton A, Tran L, Aitken R, Donaldson K. Nanoparticles, human health hazard and regulation. J. R. Soc. Interface7(Suppl. 1), S119–S129 (2010).
   PubMed Web of Science ®Google Scholar
• Semmler-Behnke M, Fertsch S, Schmid G, Wenk A, Kreyling W. Uptake of 1.4 nm versus 18 nm gold particles by secondary target organs is size dependent in control and pregnant rats after intratracheal or intravenous application. Presented at: EuroNanoForum 2007. European Commission, Düsseldorf, Germany, 19–21 June 2007.
   Google Scholar
• Takeda K, Suzuki K, Ishihara A et al. Nanoparticles transferred from pregnant mice to their offspring can damage the genital and cranial nerve systems. J. Health Sci.55, 95–102 (2009).
   Web of Science ®Google Scholar
• Chu M, Wu Q, Yang H et al. Transfer of quantum dots from pregnant mice to pups across the placental barrier. Small6, 670–678 (2010).
   PubMed Web of Science ®Google Scholar
• Myllynen PK, Loughran MJ, Howard CV, Sormunen R, Walsh AA, Vahakangas KH. Kinetics of gold nanoparticles in the human placenta. Reprod. Toxicol.26, 130–137 (2008).
   PubMed Web of Science ®Google Scholar
• Wick P, Malek A, Manser P et al. Barrier capacity of human placenta for nanosized materials. Environ. Health Perspect.118, 432–436 (2010).
   PubMed Web of Science ®Google Scholar
• Caton AR, Bell EM, Druschel CM et al. Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res. Part A Clin. Mol. Teratol.82(1), 34–40 (2008).
   PubMedGoogle Scholar
• Lowe SA, Brown MA, Dekker GA et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust. NZ J. Obstet. Gynaecol.49(3), 242–246 (2009).
   PubMed Web of Science ®Google Scholar
• Magee LA, Abalos E, von Dadelszen P, Sibai B, Walkinshaw SA. Control of hypertension in pregnancy. Curr. Hypertens. Rep.11(6), 429–436 (2009).
   PubMedGoogle Scholar
• Coppage KH, Sibai BM. Treatment of hypertensive complications in pregnancy. Curr. Pharm. Des.11(6), 749–757 (2005).
   PubMed Web of Science ®Google Scholar
• Tabacova SA, Kimmel CA. Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. Reprod. Toxicol.15(5), 467–478 (2001).
   PubMed Web of Science ®Google Scholar
• Gersak K, Cvijic M, Cerar LK. Angiotensin II receptor blockers in pregnancy: a report of five cases. Reprod. Toxicol.28(1), 109–112 (2009).
   PubMed Web of Science ®Google Scholar
• James AH, Abel DE, Brancazio LR. Anticoagulants in pregnancy. Obstet. Gynecol. Surv.61, 59–69 (2006).
   PubMedGoogle Scholar
• James AH. Pregnancy-associated thrombosis. Hematology Am. Soc. Hematol. Educ. Program277–285 (2009).
   PubMedGoogle Scholar
• Hawkins D, Evans J. Minimising the risk of heparin-induced osteoporosis during pregnancy. Expert Opin. Drug Saf.4(3), 583–590 (2005).
   PubMedGoogle Scholar
• Santoro R, Iannaccaro P, Prejanò S et al. Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy. Blood Coagul. Fibrinolysis20(4), 240–243 (2009).
   PubMedGoogle Scholar
• Lebaudy C, Hulot JS, Amoura Z et al. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin. Pharmacol. Ther.84(3), 370–377 (2008).
   PubMedGoogle Scholar
• Patel JP, Hunt BJ. Where do we go now with low molecular weight heparin use in obstetric care? J. Thromb. Haemost.6(9), 1461–1467 (2008).
   PubMedGoogle Scholar
• Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ181(1–2), 55–58 (2009).
   PubMed Web of Science ®Google Scholar
• Jamieson DJ, Honein MA, Rasmussen SA et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet374(9688), 451–458 (2009).
   PubMed Web of Science ®Google Scholar
• Rasmussen SA, Jamieson DJ, Macfarlane K et al. Pandemic influenza and pregnant women: summary of a meeting of experts. Am. J. Public Health99(Suppl. 2), S248–S254 (2009).
   PubMedGoogle Scholar
• Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro. Surveill.14(33), 19309 (2009).
   PubMedGoogle Scholar
• Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit. Care Med.33(10 Suppl.), S390–S397 (2005).
   PubMedGoogle Scholar
• Trinh QD, Izumi Y, Komine-Aizawa S et al. H3N2 influenza A virus replicates in immortalized human first trimester trophoblast cell lines and induces their rapid apoptosis. Am. J. Reprod. Immunol.62(3), 139–146 (2009).
   PubMedGoogle Scholar
• Tong A, Biringer A, Ofner-Agostini M, Upshur R, McGeer A. A cross-sectional study of maternity care providers’ and women’s knowledge, attitudes, and behaviours towards influenza vaccination during pregnancy. J. Obstet. Gynaecol. Can.30(5), 404–410 (2008).
   PubMedGoogle Scholar
• Zaman K, Roy E, Arifeen SE et al. Effectiveness of maternal influenza immunization in mothers and infants. N. Engl J. Med.359(15), 1555–1564 (2008).
   PubMed Web of Science ®Google Scholar
• Granwehr BP. Influenza immunisation during pregnancy reduced influenza in infants and respiratory illness in mothers. Evid. Based Med.14(2), 55 (2009).
   PubMedGoogle Scholar
• Power ML, Leddy MA, Anderson BL, Gall SA, Gonik B, Schulkin J. Obstetrician–gynecologists’ practices and perceived knowledge regarding immunization. Am. J. Prev. Med.37(3), 231–234 (2009).
   PubMed Web of Science ®Google Scholar
• Wutzler P, Schmidt-Ott R, Hoyer H, Sauerbrei A. Prevalence of influenza A and B antibodies in pregnant women and their offspring. J. Clin. Virol.46(2), 161–164 (2009).
   PubMedGoogle Scholar
• Marx H, Amin P, Lazarus JH. Hyperthyroidism and pregnancy. Br. Med. J.336(7645), 663–667 (2008).
   PubMed Web of Science ®Google Scholar
• Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J. Clin. Endocrinol. Metab.86(6), 2354–2359 (2001).
   PubMed Web of Science ®Google Scholar
• Browne ML, Rasmussen SA, Hoyt AT et al. Maternal thyroid disease, thyroid medication use, and selected birth defects in the National Birth Defects Prevention Study. Birth Defects Res. Part A Clin. Mol. Teratol.85(7), 621–628 (2009).
   PubMed Web of Science ®Google Scholar
• Momotani N, Ito K, Hamada N, Ban Y, Nishikawa Y, Mimura T. Maternal hyperthyroidism and congenital malformation in the offspring. Clin. Endocrinol. (Oxf.)20(6), 695–700 (1984).
   PubMed Web of Science ®Google Scholar
• Chan GW, Mandel SJ. Therapy insight: management of Graves’ disease during pregnancy. Nat. Clin. Pract. Endocrinol. Metab.3(6), 470–478 (2007).
   PubMedGoogle Scholar
• Abalovich M, Amino N, Barbour LA. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab.92(Suppl. 8), S1–S47 (2007).
   PubMed Web of Science ®Google Scholar
• Okosieme OE, Marx H, Lazarus JH. Medical management of thyroid dysfunction in pregnancy and the postpartum. Expert Opin. Pharmacother.9(13), 2281–2293 (2008).
   PubMed Web of Science ®Google Scholar
• Bach-Huynh T-G, Jonklaas J. Thyroid medications during pregnancy. Ther. Drug Monit.28, 431–441 (2006).
   PubMed Web of Science ®Google Scholar
• Clark SM, Saade GR, Snodgrass WR, Hankins GD. Pharmacokinetics and pharmacotherapy of thionamides in pregnancy. Ther. Drug Monit.28(4), 477–483 (2006).
   PubMed Web of Science ®Google Scholar
• Lagerberg RE. Malaria in pregnancy: a literature review. J. Midwifery Womens Health53(3), 209–215 (2008).
   PubMed Web of Science ®Google Scholar
• Omo-Aghoja LO, Abe E, Feyi-Waboso P, Okonofua FE. The challenges of diagnosis and treatment of malaria in pregnancy in low resource settings. Acta Obstet. Gynecol. Scand.87(7), 693–696 (2008).
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D. Pregnancy and epilepsy: what should we tell our patients? J. Neurol.256, 856–862 (2009).
   PubMedGoogle Scholar
• Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia50, 2163–2166 (2009).
   PubMedGoogle Scholar
• Meador KJ, Baker GA, Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med.360, 1597–1605 (2009).
   PubMed Web of Science ®Google Scholar
• Tarning J, McGready R, Lindegardh N et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether–lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother.53, 3837–3846 (2009).
   PubMed Web of Science ®Google Scholar
• McKoy JM, Bennett CL, Scheetz MH et al. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf.32, 147–155 (2009).
   PubMed Web of Science ®Google Scholar